Structure Therapeutics Inc. (NASDAQ:GPCR) is identified as one of the best small-cap biotech stocks to buy by analysts, with significant upside potential. BMO Capital maintains an “Outperform” rating and sets a $100 price target, citing upcoming obesity trial readouts as potential market boosters. The company reported Q3 2025 results with a net loss of $65.7 million, but a strong cash position of $799 million.

The company, known for developing oral small-molecule treatments for metabolic diseases, is focused on ongoing obesity studies and oral amylin receptor agonist programs. Research costs hit $59 million in Q3, with a net loss increase from the previous year. Despite losses, Structure Therapeutics Inc. (NASDAQ:GPCR) maintains a solid cash position to support future development and studies through 2026.

Investors are advised to consider AI stocks for greater upside potential and lower downside risk than Structure Therapeutics Inc. (NASDAQ:GPCR). For those seeking undervalued AI stocks with potential benefits from Trump-era tariffs and onshoring trends, a free report on the best short-term AI stock is recommended. No disclosure information is provided in the news article.

Read more at Yahoo Finance: BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts